The Annexure

News to 9 October 2026 ·

Desk›Healthcare› Divis Laboratories Ltd

Divis Laboratories Ltd

BSE 532488 · NSE DIVISLAB · ISIN INE361B01024 · Group A · Active

Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals

₹9,050.00

+0.39%

BSE close, 28 August 2026

Market cap

₹240,249.06 cr

26.5 cr shares · Large cap

Free float

₹114,470.51 cr

as published

P/E · P/B

81.7× · 17.62×

EPS ₹110.79 · BV ₹513.62

FY25-26 rev / PAT

10,388.00 / 2,607.00

₹ cr, as filed

Filings, window

9

2 selected · 22%

Regime

Reg 30

Sch. III Part A

Price 52-week, BSE

52-WK LOW ₹5,637.50 52-WK HIGH ₹9,148.05 ₹9,050.00 97% of range
Against 52-week high-1.1%
Against 52-week low+60.5%
Day change+0.39%
Size bandLarge cap
Index membershipNIFTY 500

Valuation as published by BSE

Earnings per share₹110.79
Price / earnings81.69×
Price / book17.62×
Book value — derived, price ÷ P/B₹513.62
Return on equity21.57%
Operating margin43.81%
Net margin29.96%

Consistency check

P/B ÷ P/E, which must equal ROE
21.57%
ROE as published
21.57%

Results ₹ crore, as filed

RevenueNet profit one scale across all three periods, ₹ crore

PeriodRevenue ₹cr Net profit ₹cr EPS ₹OPM NPM
Jun-26 · Q 2,974.00 891.00 33.55 43.81% 29.96%
Mar-26 · Q 2,793.00 756.00 28.44 39.28% 27.07%
FY25-26 10,388.00 2,607.00 98.19 37.74% 25.10%

Quarter on quarter

Revenue, quarter on quarter
+6.5%
Net profit, quarter on quarter
+17.9%
Operating margin, quarter on quarter
+453 bps

Disclosure profile 9 filings in the window

0 median 17.0 p75 · 25 sector max 52 9 11th percentile of 300 Healthcare filers
Shaded is the middle half of the sector, 12 to 25 filings. Measured against the 300 Healthcare companies that filed at all in this window — companies with no filings are excluded, so this is a percentile against filers rather than against the sector.
TagFilings
Selected
Change in Management1
Concall Transcript1
Selected sub-total2
Procedural
AGM / EGM2
Analyst / Investor Meet1
Board Meeting1
Compliance Certificate1
Newspaper Publication1
Trading Window1
Procedural sub-total7
Total9

Disclosure regime

LODR Reg 30

Read with Schedule III Part A. An equity filer in BSE Group A, so the Regulation 30 disclosure framework and the Schedule III event list both apply.

Sources Price, day change, 52-week range — bse.quote, bse.quoteWeeklyHL, 28 August 2026 close. Market cap and free float — bse.getScripTradingStats. P/E, P/B, EPS, ROE, margins — bse.equityMetaInfo. Quarterly and annual results — bse.resultsSnapshot, standalone, as filed. Four-tier classification — data/reference/companies.csv. Filing counts and tags — the build aggregate for this window. Notes Book value is derived as price ÷ P/B; BSE does not publish it directly. Share count is derived as market cap ÷ price. Figures move between captures and between vendors, and the two are not an error in either: companies.csv carries the market cap from an earlier sweep than the snapshot above. EPS appears twice with different meanings — the figure beside P/E is the trailing one from equityMetaInfo, while the EPS in the results table is the per-period figure as filed.

Filing rhythm · 93 trading days

9 filings · 2 selected · busiest 2026-08-10

Filing rhythm · the twelve most recent

2026-07-202026-10-06

SelectedProcedural

Filings

9 in the window · 9 earlier on record

  1. 6 October 2026 ·

    Compliance Certificate

    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended September 30, 2026

    Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 View filing →

  2. 30 September 2026 ·

    Trading Window

    Closure of Trading Window

    Intimation of closure of Trading Window from 01.10.2026 till 48 hours of declaration of financial results for the quarter and half year ended 30.09.2026.

    Insider Trading / SAST / Closure of Trading Window View filing →

  3. 10 August 2026 ·

    AGM / EGM

    Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    Submission of Scrutinizer's report on 36th AGM resolutions.

    AGM/EGM / AGM View filing →

  4. 10 August 2026 ·

    AGM / EGM

    Shareholder Meeting / Postal Ballot-Outcome of AGM

    Outcome of 36th AGM - submission of AGM proceedings, voting results and Scrutinizer's report.

    AGM/EGM / AGM View filing →

  5. 6 August 2026 ·

    Concall Transcript

    Earnings Call Transcript

    Submission of transcript of Earnings Conference Call held on August 01, 2026

    Company Update / Earnings Call Transcript View filing →

  6. 3 August 2026 ·

    Newspaper Publication

    Newspaper Publication

    Newspaper clippings regarding unaudited financial results of the Company for the quarter ended June 30, 2026

    Company Update / Newspaper Publication View filing →

  7. 31 July 2026 ·

    Change in Management

    Change in Management

    Intimation of retirement of Senior Management Personnel as detailed in the enclosed letter.

    Company Update / Change in Management View filing →

  8. 24 July 2026 ·

    Analyst / Investor Meet

    Analyst / Investor Meet - Intimation

    Schedule of earnings conference call for Q1 FY27

    Company Update / Analyst / Investor Meet View filing →

  9. 20 July 2026 ·

    Board Meeting

    Board Meeting Intimation for Considering And Approving The Unaudited Financial Results Of The Company For The Quarter Ended June 30, 2026.

    Divis Laboratories Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/08/2026 ,inter alia, to consider and approve the unaudited financial ....

    Board Meeting / Board Meeting View filing →

RSS feed for Divis Laboratories Ltd · the 50 most recent filings